Medica said its shares were flagged for abnormal trading volatility after the cumulative deviation in closing-price gains reached 30% over three consecutive sessions on June 15, 2026, June 16, 2026, and June 17, 2026.
According to Jin10, the company said market attention has recently focused on the “glass substrate” concept, but the semiconductor glass substrates it supplies to customers are undrilled substrates. Medica said revenue from related products accounted for about 2.00% of total revenue in 2025. It added that its through-glass via (TGV) processes, including glass via formation and in-via metallization, have not yet generated mass-production revenue.
Medica also said it entered Samsung’s supply chain through an acquisition. In 2025, revenue from that business accounted for less than 2.50% of total revenue, and the products involved were flexible film filters used for mobile phone camera modules. The company added that its wafer-level packaging and testing business for power chips has not yet generated mass-production revenue.
Medica said its production and operations are normal, and its controlling shareholder and actual controller have no major matters that should be disclosed but have not been disclosed.
Weatherly